Entrada Therapeutics (TRDA) 10% Owner MPM BioVentures Sells Shares

What Happened
MPM BioVentures (reported as a 10% owner across affiliated funds) sold a total of 86,914 Entrada Therapeutics (TRDA) shares in three open-market transactions between August 27 and August 31, 2026. The individual trades were: 38,922 shares at a weighted average $7.20 (≈ $280,238) on Aug 27; 3,733 shares at $7.01 (≈ $26,168) on Aug 28; and 44,259 shares at $6.99 (≈ $309,370) on Aug 31. Total proceeds across the three sales were about $615,776. These were sales (S) — not purchases or option exercises.

Key Details

• Transaction dates and reported weighted-average prices: Aug 27 (38,922 @ $7.20), Aug 28 (3,733 @ $7.01), Aug 31 (44,259 @ $6.99). Reported sale-price range across trades: $6.76–$7.37 per share (footnotes).
• Total shares sold: 86,914; total proceeds: ≈ $615,776.
• Holdings after the transactions (across related MPM entities): each affiliated fund still holds multi‑million share stakes — e.g., BV 2018 ~1.99M shares and BV 2014 ~1.94M shares (see filing footnotes for full breakdown).
• These sales were allocated among several affiliated MPM entities (BV 2014, BV 2014(B), AM BV2014, BV 2018, BV 2018(B), AM BV2018) (see footnote F1).
• No 10b5-1 plan, tax-withholding, or option-exercise language is indicated in the provided footnotes; transactions are reported as open‑market sales.
• Filed Aug 31, 2026 (check related Form 4s for other affiliated filers noted in the remarks).

Context
This filing reports institutional selling by a large shareholder (a set of affiliated venture funds), not an insider executive. Institutional sales can be routine portfolio-management activity and do not on their own indicate management sentiment. For full detail and exact per-price breakdowns, refer to the Form 4 footnotes and the related filings by MPM BioVentures 2014, L.P.